Beteiligungsmeldung

Idorsia Ltd

Gemeinsam gemeldeter Anteil

32.5%

Threshold

Crossed upwards

Timeline

Published

04.03.2025

Transaction

25.02.2025

Voting rights breakdown

Erworbene Stimmrechte32.5%
Veräusserte Stimmrechte0%
Unter dem Schwellenwert0%

Gemeldete wirtschaftlich Berechtigte · 2

Eine einzelne, gemeinsam eingereichte Meldung: Der Stimmrechtsanteil gilt für die gesamte Gruppe, nicht für jede Person.

Notice details

KategorieGroup of shareholders
BörseXSWX

Meldungs-ID

ZA02-000000000PUI7

Beneficial owner

Jean-Paul Clozel

Gemeldete Adresse

Jean-Paul Clozel, Binningen, CH

Date of transfers of equity securities: expected between Q1 and Q3 of 2025 Jean-Paul Clozel has entered into into a lock-up agreement dated February 25, 2025 with, among others, Idorsia Ltd (the "Company"), Idorsia Pharmaceuticals Ltd ("IPL") and certain other bondholders (the "Lock-Up Agreement") and a backstop letter agreement dated February 25, 2025 with the Company, IPL and certain other bondholders (the "Backstop Letter", collectively the "Agreements"), and is thus a member of the lock-up group disclosed as of March 3, 2025. Thus this disclosure notification includes only the positions held by Jean-Paul Clozel, which are not locked under the Lock-Up Agreement and, hence are not covered by the lock-up group disclosure. Under the Agreements, Jean-Paul Clozel holds the rights to receive (positions which were allocated but not delivered, and some of which may change before final delivery): (i) to receive 4,410,490 registered shares as per different conditions and milestone events as defined in the Agreements between approximately Q1 2025 and up until Q3 2025 as follows: a) 600,000 registered shares as a backstop fee (allocated but not delivered); b) 700,000 registered shares as an arrangement fee (subject to change before final delivery); and c) 3,110,490 registered shares as an exchange fee (subject to change before final delivery). (ii) to be granted/issued warrants between approximately Q1 2025 and approximately end of Q3 2025 as per different conditions and milestone events as defined in the Agreements that (1) will have a maturity based on the maturity of the new money facility pursuant to the Lock-Up Agreement (i.e., 24 months from first utilisation of the new money facility), and (2) an exercise price of CHF 1.50 per warrant for the delivery of up to 4,277,154 registered shares as follows: a) up to 533,332 registered shares as a backstop fee (allocated but not delivered); b) up to 633,332 registered shares as an arrangement fee (subject to change before final delivery); and c) up to 3,110,490 registered shares as an exchange fee (subject to change before final delivery). The previous positions regarding (1) the convertible bonds 2025 (ISIN CH0426820350; 0.75 IDORSIA CV 18-25) issued by the Company (the "CB25") and (2) the convertible bonds 2028 (ISIN CH1128004079; 2.125 IDORSIA CV 21-28) issued by the Company (the "CB28"): a) 9,466,667 voting rights with regard to CB25; and b) 5,516,804 voting rights with regard to CB28, are now covered by the separate lock-up group disclosure regarding the lock-up group, as disclosed as of March 3, 2025.

Diese Zahlen fassen öffentliche Meldungen zusammen. Sie stellen keine Anlageberatung dar.

Quelle: SIX Exchange Regulation

insider24.ch

Verpassen Sie kein Marktsignal mehr

Pro-AlarmeE-Mail und Telegram nach Veröffentlichung
Unbegrenzt Unternehmen verfolgenUnbegrenzte Watchlist mit dem Pro-Plan
MontagsrückblickDas Wichtigste zu Ihren Werten zur Eröffnung